Colorectal Cancer Drug Fizzles in Pivotal Phase III Trial
Aeterna Zentaris’ colorectal cancer drug perifosine did not meet its primary endpoint of median overall survival in a key Phase III trial, potentially putting the skids on the compound.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.